SEC Tracker
Get the app

Replimune Group REPL

Patel Sushil (Chief Strategy Officer) plans to sell 10,000 REPL shares, about $111,303

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Dec 2, 2025
  2. Broker: J.P. Morgan Securities LLC
  3. Shares acquired by: Stock Options
  4. 10b5-1 plan adopted: Jun 2, 2025

All of Patel Sushil's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 10,000 shares at $11.13 on Dec 2, 2025 · Form 4

Written from the Form 144 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Replimune Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  2. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Annexon ANNX public float $244M, Jun 30, 2025
  5. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025